At the end of experimental period, the rats were sacrificed under anesthesia and blood was immediately collected. The total serum cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) levels were measured by ELISA kit (Nanjing jiancheng Bioengineering Institute, Nanjing, China). The fast serum insulin (FINS) concentration was measured using the commercial kits (Wa Lan Biotechnology, Shanghai, China). Insulin sensitivity index (ISI) was calculated according to FBG and FINS. The formula of ISI used was given: Ln (1/FBG*FINS) . Homeostasis model assessment-insulin resistance (HOMA-IR) was calculated to measure the insulin sensitivity of the rats fed the experimental diets by the following formula: [FINS×FBG] 22.5-1. 70 rats were randomly divided into two groups: normal control group (NC, n=10) and the diabetic rats group (n=60). The NC group was fed with regular diet. The diabetic rats group was fed with a high-sugar and high fat diet (HFD), containing 5% sucrose, 10% lard, 5% yolk powder, 1% cholesterol, 0.1% sodium cholate and 78.9 % regular diet. After four-week dietary intervention, the diabetic rats were fasted for 24 h and then received STZ (35 mg kg-1) dissolved in citrate buffer (0.1 M, pH 4.5) by intraperitoneal injection. Rats in the NC group received equivalent citrate buffer vehicle. One week after injection, fasting blood glucose (FBG) levels were determined using a drop of blood from the tail vein. The rats with FBG level above 11.1 mM were randomly subdivided into four groups (n=13 for each group): diabetic model group (DM) and three treatment groups. The treatment groups were fed with 0.67 mg kg-1 of metformin hydrochloric (HM), 20 g kg-1 of GQD, and 20 g kg-1 of FGQD (crude drug per g kg-1 of body weight) every day, respectively for eight weeks.
5. How many times each experiment shown was replicated and an indication of the extent of variation from experiment to experiment. 6. Information on the statistical methods and measures used. It should be clear whether the tests are one-sided or two-sided, whether there are adjustments for multiple comparisons, whether medians or means are being shown, whether error bars are standard deviations (SD), standard error of mean (SEM) or confidence intervals. 7. A justification for the appropriateness of statistical tests used to assess significance. Do the data meet the assumptions of the tests? Is there an estimate of variation within each group of data, and is the variance similar between groups that are being statistically compared? In addition, information essential to interpreting the data presented should be made available in the figure and table legends. If the study involves health interventions for human participants, please refer to the relevant reporting guidelines from the EQUATOR Network, and the Biosharing Portal for reporting checklists for biological and biomedical research, where applicable.
Research involving humans
If your research involved humans, please confirm you have adhered to the relevant reporting guideline from the EQUATOR Network, and included the completed checklist as an additional file with your submission:
Answer (page and line number inserted/Not applicable for my study) -I have followed the relevant reporting for my study type, and included a populated checklist with my submission -Not applicable for my study GQD and FGQD samples were prepared in triplicate. To validate the stability of sample preparation and instrument, a pooled sample of all samples was prepared as quality control samples (QCs) for LC-MS. QCs were injected six times before the batch process and injected one time every twelve samples during the analysis process.
Data were expressed as mean ± S.D. Statistical significances between means were determined using one-way ANOVA followed by the LSD test of variance homogeneity and Dunnettʼs T3 test in variance heterogeneity after normal distribution test.
Unless specified, a value of p<0.05 was selected for discriminating significant differences throughout.
Resources
A description of all resources used should be included in the Methods section, with enough information to allow them to be uniquely identified. The table below should be completed with confirmation that this was done (i.e. included in the Methods section) or is not applicable. If this has not been completed, but is applicable, you should contact the journal editorial staff before proceeding.
Answer (page and line number inserted/Not applicable for my study)
•Antibodies: report source, catalogue code, characteristics, dilutions and how they were validated for the system under study.
•Cell lines: report source, whether identity has been authenticated and whether tested for mycoplasma contamination. We encourage researchers to check the NCBI database for contamination of cell lines.
•Organisms: report source, species, strain, sex, age, husbandry, inbred and strain characteristics of transgenic and mutant animals.
•Tools (software, databases and services): report standard tool name, provider and version number, if available. For antibodies, model organisms (mice, zebrafish and flies) and tools, authors are strongly encouraged to cite Research Resource Identifiers (RRIDs). To do so, please go to the Resource Identification Portal to search for your research resource and insert the reference text into your Methods section.
Not applicable for my study.
Not applicable for my study. Data from HPLC Q Exactive MS acquisition and processing were performed using XcaliburTM 2.2 (Thermo Fisher) for chemical profile analysis. The untargeted metabolomics analysis was conducted by the Compound Discovery (version 1.2.1, Thermo SCIEX).The multivariate data matrix was introduced to SIMCA-P (Version 13.0, Umetrics AB, Umea, Sweden) software. All the grouped data were statistically performed with SPSS 13.0 for animal experiment.
